There is considerable evidence in the literature that deaths due to the simultaneous abuse of ethanol with opioids such as heroin or prescription opioids leads to lower blood levels of the opioid upon autopsy than is observed following death due to the opioid alone. We have carried out an extensive study which has shown that either ethanol or diazepam at doses that do not alter the acute effects of morphine reversed the antinociceptive tolerance produced by chronic morphine. The mechanism of the reversal produced by the two drugs differed in that inhibitors of either GABAA or GABAB receptors alone did not reverse the effect of alcohol but blocking both type GABA receptors completely reversed the effect of ethanol on morphine tolerance. Conversely the inhibition of morphine tolerance produced by diazepam was completely reversed by a GABAA inhibitor alone but not by the GABAB inhibitor. The overall objective of the work described in this proposal is to elucidate the cellular mechanisms by which opioid tolerance is reversed by the concomitant administration of ethanol and other agents affecting the central nervous system. Using genetically altered mice and a number of molecular techniques we will elucidate further the role of GABA receptors and the signaling mechanisms involved in these effects. In the second specific aim we propose to elucidate whether ethanol and diazepam reverses the tolerance to opioids such as buprenorphine and methadone which are used in maintenance therapy and oxycodone and other prescription opioids with a history of abuse. We and others have reported differences in the mechanism of tolerance development for various opioids. For instance, protein kinase A and protein kinase C inhibitors but not GIRK inhibitors reversed tolerance to morphine and other moderately efficacious opioids but not to the high efficacy DAMGO. GIRK inhibitors revered the tolerance to DAMGO but not the other opioids. These differences in the mechanism of tolerance development to various opioids cause us to investigate whether ethanol and/or diazepam will reverse the tolerance to opioids of various efficacies. Obviously, we will elucidate the differing mechanisms if the opioids are affected differently by ethanol or diazepam. In the third specific aim we will investigate whether ethanol and diazepam also reverse tolerance to a peripheral effect of opioids. We and others have found certain differences between the mechanisms of opioid tolerance in the brain and the gastrointestinal tract and now we propose to determine whether ethanol and/or diazepam reverses opioid tolerance in the gastrointestinal tract. The information gained from these experiments will provide important information as we and others continue to elucidate the mechanism of opioid tolerance.

Public Health Relevance

It is clear from the literature that the vast majority of individuals who use opiates chronically also consume alcohol or other central nervous system depressants. It also has been reported that the consumption of alcohol potentiates the lethal and other effects of opioids and that blood levels of morphine and other opioids are lower in autopsy of individuals who have consumed alcohol than in people who die from the opioid alone. The overall goal of the work described in this proposal is to elucidate the mechanisms underlying these events.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA036975-03
Application #
9088393
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Purohit, Vishnudutt
Project Start
2014-07-01
Project End
2019-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Lyndon, Abigail; Audrey, Suzanne; Wells, Claudia et al. (2017) Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction 112:1580-1589
Akbarali, Hamid I; Dewey, William L (2017) The gut-brain interaction in opioid tolerance. Curr Opin Pharmacol 37:126-130
Withey, Sarah L; Hill, Rob; Lyndon, Abigail et al. (2017) Effect of Tamoxifen and Brain-Penetrant Protein Kinase C and c-Jun N-Terminal Kinase Inhibitors on Tolerance to Opioid-Induced Respiratory Depression in Mice. J Pharmacol Exp Ther 361:51-59
Gonek, Maciej; Akbarali, Hamid I; Henderson, Graeme et al. (2017) Reversal of oxycodone and hydrocodone tolerance by diazepam. Brain Res 1674:84-90
Bhave, Sukhada; Gade, Aravind; Kang, Minho et al. (2017) Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation. FASEB J 31:2649-2660
Jacob, Joanna C; Poklis, Justin L; Akbarali, Hamid I et al. (2017) Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone. J Pharmacol Exp Ther 362:45-52
Gonek, Maciej; McLane, Virginia D; Stevens, David L et al. (2017) CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Brain Behav Immun :
Gade, Aravind R; Kang, Minho; Khan, Fayez et al. (2016) Enhanced Sensitivity of ?3?4 Nicotinic Receptors in Enteric Neurons after Long-Term Morphine: Implication for Opioid-Induced Constipation. J Pharmacol Exp Ther 357:520-8
Williams, Dwight A; Zheng, Yi; David, Bethany G et al. (2016) 6?-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand. ACS Chem Neurosci 7:1120-9
Zhang, Yan; Williams, Dwight A; Zaidi, Saheem A et al. (2016) 17-Cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion. ACS Chem Neurosci 7:297-304

Showing the most recent 10 out of 13 publications